Immupharma news. Headlines for IMM.

Immupharma News

Prices

Results Calendar charts

Charts

Watchlist

Share Tips

Here are all todays headlines related to Immupharma News. If you wish to drill deeper to view past Immupharma News items, follow the next 20 headlines link at the foot of the page.

Immupharma finds potential alternate indications for Lupus treatment

14-06-2018

Drug discovery and development firm Immupharma on Thursday revealed that its pre-clinical work on P140, a peptide being developed as a Lupus treatment, may have other potential indications.

ImmuPharma impresses with mixed data from lupus trial

29-05-2018

Drug discovery and development company ImmuPharma saw losses widen in its last trading year, but fresh analysis of results from its pivotal Phase III trial on its Lupus treatment has given both the firm and its investors some reason to be optimistic.

ImmuPharma tanks after disappointment with lupus study

17-04-2018

A recent Phase III study undertaken by drug discovery and development company ImmuPharma demonstrated a superior response rate from its lupus compound, Lupuzor, but, due to a high response rate in the placebo group, the group's superior response was unable to allow statistical significance to be reached and the trial's primary endpoint was not met.

Friday broker round-up

23-03-2018

Mitie Group: Barclays upgrades to overweight with a target price of 180p.

ImmuPharma anticipating latest Lupuzor test results in April

23-03-2018

Specialist drug discovery and development company ImmuPharma announced on Friday that it has been informed by Simbec-Orion, the contract research organisation conducting its 'Lupuzor' pivotal Phase III trial study, that 'database lock' was expected on 6 April, with top line results announced by mid-April.

Tuesday broker round-up

24-01-2018

Countrywide: Berenberg upgrades to hold with a target price of 95p.

ImmuPharma raises £10m following investor demans

24-01-2018

Specialist drug discovery and development company ImmuPharma announced on Wednesday that, in response to institutional demand, it has completed a fundraise totalling £10m before expenses via a placing of 6,944,445 new ordinary shares at a price of 144p per share, with new and existing investors.

Thrusday broker round-up

18-01-2018

Rightmove: JP Morgan upgrades to neutral with a target price of 4,168p.

Next 20 headlines >>

Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk

Get a free widget for your website with our latest headlines.

You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.

Visit our widget builder